Chemoprevention of lung carcinogenesis by the combination of aerosolized budesonide and oral pioglitazone in A/J mice

Molecular Carcinogenesis

Volumn 50, Issue 12, 2011, Pages 913-921

  Fu, Huijing ^a   Zhang, Jingjie ^a   Pan, Jing ^b   Zhang, Qi ^b   Lu, Yan ^b   Wen, Weidong ^b   Lubet, Ronald A ^c   Szabo, Eva ^c   Chen, Ruth ^a   Wang, Yian ^b   Chen, Da Ren ^a   You, Ming ^b  

^a WASHINGTON UNIVERSITY IN ST LOUIS   (United States)

^b USA   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Budesonide; Chemoprevention; Lung tumorigenesis; Mouse; Pioglitazone

Indexed keywords

BUDESONIDE; PIOGLITAZONE;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CARCINOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZO(A)PYRENE; BUDESONIDE; CARCINOGENS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CHEMOPREVENTION; FEMALE; GLUCOCORTICOIDS; HUMANS; LUNG; LUNG NEOPLASMS; MICE; MICE, INBRED A; THIAZOLIDINEDIONES;

MUS;

EID: 80155129711     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20751     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Hecht SS, Kassie F, Hatsukami DK. Chemoprevention of lung carcinogenesis in addicted smokers and ex-smokers. Nat Rev Cancer 2009; 9: 476-488.
3. Lippman SM, Lee JJ, Sabichi AL. Cancer chemoprevention: Progress and promise. J Nat Cancer Inst 1998; 90: 1514-1528.
4. Tatsumura T, Koyama S, Tsujimoto M, Kitagawa M, Kagamimori S. Further study of nebulisation chemotherapy, a new chemotherapeutic method in the treatment of lung carcinomas: Fundamental and clinical. Br J Cancer 1993; 68: 1146-1149.
5. Verschraegen CF, Gilbert BE, Loyer E, et al. Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies. Clin Cancer Res 2004; 10: 2319-2326.
6. Fu HJ, He J, Mei F, et al. Lung cancer inhibitory effect of epigallocatechin-3-gallate is dependent on its presence in a complex mixture (polyphenon E). Cancer Prev Res 2009; 2: 531-537.
7. Wattenberg LW, Estensen RD. Studies of chemopreventive effects of budenoside on benzo[a]pyrene-induced neoplasia of the lung of female A/J mice. Carcinogenesis 1997; 18: 2015-2017.
8. Wattenberg LW, Wiedmann TS, Estensen RD, Zimmerman CL, Steele VE, Kelloff GJ. Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice. Cancer Res 1997; 57: 5489-5492.
9. Yao RS, Wang Y, Lemon WJ, Lubet RA, You M. Budesonide exerts its chemopreventive efficacy during mouse lung tumorigenesis by modulating gene expressions. Oncogene 2004; 23: 7746-7752.
10. Wattenberg LW, Wiedmann TS, Estensen RD, et al. Chemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myo-inositol. Carcinogenesis 2000; 21: 179-182.
11. Alyaqoub FS, Tao LH, Kramer PM, et al. Prevention of mouse lung tumors and modulation of DNA methylation by combined treatment with budesonide and R115777 (Zarnestra(MT)). Carcinogenesis 2007; 28: 124-129.
12. Nemenoff RA. Peroxisome proliferator-activated receptor-gamma in lung cancer: Defining specific versus "off-target" effectors. J Thorac Oncol 2007; 2: 989-992.
13. Lehrke M, Lazar MA. The many faces of PPARγ. Cell Mol Immunol 2005; 123: 993-999.
14. Michalik L, Desvergne B, Wahli W. Peroxisome-proliferator-activated receptors and cancers: Complex stories. Nat Rev Cancer 2004; 4: 61-70.
15. Theocharis S, Kanelli H, Politi E, et al. Expression of peroxisome proliferator activated receptor-γ in non-small cell lung carcinoma: Correlation with histological type and grade. Lung Cancer 2002; 36: 249-255.
16. Nemenoff RA, Weiser-Evans M, Winn RA. Activation and molecular targets of peroxisome proliferator-activated receptor-gamma ligands in lung cancer. PPAR Res 2008; (Article ID 156875), 8 pages.
17. Keshamouni VG, Reddy RC, Arenberg DA, et al. Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 2004; 23: 100-108.
18. Satoh T, Toyoda M, Hoshino H, et al. Activation of peroxisome proliferator-activated receptor-gamma stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells. Oncogene 2002; 21: 2171-2180.
19. Shah P, Mudaliar S. Pioglitazone: Side effect and safety profile. Expert Opin Drug Saf 2010; 9: 347-354.
20. Gegick CG, Altheimer MD. Comparison of effects of thiazolidinediones on cardiovascular risk factors: Observations from a clinical practice. Endocr Pract 2001; 7: 162-169.
21. Stafylas PC, Sarafidis PA, Lasaridis AN. The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality. Int J Cardiol 2009; 131: 298-304.
22. Wang Y, James M, Wen W, et al. Chemopreventive effects of pioglitazone on chemically induced lung carcinogenesis in mice. Mol Cancer Ther 2010; 9: 3074-3082.
23. Zhang Z, Liu Q, Lantry LE, et al. A germ-line p53 mutation accelerates pulmonary tumorigenesis: p53-independent efficacy of chemopreventive agents green tea or dexamethasone/myo-inositol and chemotherapeutic agents taxol or adriamycin. Cancer Res 2000; 60: 901-907.
24. Guyton AC. Measurement of the respiratory volumes of laboratory animals. Am J Physiol 1947; 150: 70-77.
25. White MJ, DiCaprio MJ, Greenberg DA. Assessment of neuronal viability with Alamar blue in cortical and granule cell cultures. J Neurosci Methods 1996; 70: 195-200.
26. Han S, Roman J. Rosiglitazone suppresses human lung carcinoma cell growth through PPARγ-dependent and PPARγ-independent signal pathways. Mol Cancer Ther 2006; 5: 430-437.
27. Keshamouni VG, Arenberg DA, Reddy RC, Newstead MJ, Anthwal S, Standiford TJ. PPAR-gamma activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer. Neoplasia 2005; 7: 294-301.
28. Hazra S, Batra RK, Tai HH, Sharma S, Cui XY, Dubinett SM. Pioglitazone and rosiglitazone decrease prostaglandin E-2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase. Mol Pharmacol 2007; 71: 1715-1720.
29. Raabe OG, Al-Bayati MA, Teague SV, Rasolt A. Regional deposition of inhaled monodisperse coarse and fine aerosol particles in small laboratory animals. Ann Occup Hyg 1988; 32: 53-63.
30. Dahl AR, Grossi IM, Houchens DP, et al. Inhaled isotretinoin (13-cis retinoic acid) is an effective lung cancer chemopreventive agent in A/J mice at low doses: A pilot study. Clin Cancer Res 2000; 6: 3015-3024.
31. Liao XM, Liang W, Wiedmann T. Lung distribution of the chemopreventive agent difluoromethylornithine (DFMO) following oral and inhalation delivery. Exp Lung Res 2004; 30: 755-769.
32. Ondrey F. Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: Implications for chemoprevention. Clin Cancer Res 2009; 15: 2-8.